Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Cidara Therapeutics, Inc. (CDTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/14/2023 4 Tari Leslie (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns: Bought 10,000 shares @ $0.97, valued at $9.7k
08/08/2023 4 Stein Jeffrey (President & CEO) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns: Bought 50,000 shares @ $0.9577, valued at $47.9k
08/03/2023 8-K Quarterly results
Docs: "Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/11/2023 8-K Quarterly results
Docs: "Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 8-K Quarterly results
Docs: "Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results"
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 4 Ward Shane (COO & CLO) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns: Sold 4,329 shares @ $1.53, valued at $6.6k
03/13/2023 4 Tari Leslie (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns: Sold 7,562 shares @ $1.53, valued at $11.6k
03/13/2023 4 Shah Preetam (CFO & CBO) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns: Sold 6,648 shares @ $1.53, valued at $10.2k
03/13/2023 4 Sandison Taylor (Chief Medical Officer) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns: Sold 7,203 shares @ $1.53, valued at $11k
03/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Common Stock)",
"Underwriting Agreement, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Series X Convertible Preferred Stock)",
"Opinion of Cooley LLP"
03/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/02/2023 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
03/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/01/2023 8-K Quarterly results
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 6.1% stake in CIDARA THERAPEUTICS, INC.
02/14/2023 8-K Quarterly results
01/27/2023 4 Tari Leslie (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns: Sold 11,814 shares @ $1.2, valued at $14.2k
12/16/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy